Handbook of Multiple Sclerosis [electronic resource] / by Jeffrey A Cohen, Alexander Rae-Grant.

Clinical features -- Diagnosing multiple sclerosis -- Treatment of acute relapses of multiple sclerosis -- Disease-modifying therapy -- Symptom management -- Medical management of patients with multiple sclerosis.

A comprehensive guide to multiple sclerosis, discussing: clinical features, diagnosis, disease-modifying therapy, & symptom & medical management written by world-renowned experts in neurology, specifically MS. Dr Cohen and Dr Rae-Grant who are renowned researchers and physicians in the field of MS and are investigators on several key drug trials. Extensive use of illustrations and succinct format makes this book an easily accessible and key reference guide. Reviews cutting-edge agents currently in development, while also discussing the clinical features and standard diagnosing criteria and practices of MS from the clinicians perspective Designed to include thorough descriptions of standard and novel treatment therapies in MS. Explains how to most effectively use the top therapies in MS in the context of a clinical practice and based on investigational trials. Concise but comprehensive Over the past 30 years, there have been significant advances in our understanding of MS due to the use of MRIs to better visualize the disease and due to the introduction of new ameliorating drugs. However, MS is still an incurable disease and diagnosis remains challenging for many physicians; for instance, symptoms often mimic MS, and there is no specific test for the disease. To ensure optimal patient care, there is a need for physicians to remain up to date with new drugs on the market, disease detection, diagnosis, and latest management options. The Handbook of Multiple Sclerosis provides a concise, easily accessible guide for all healthcare professionals involved in the diagnosis and management of this condition, including standard therapies, as well as more novel treatments. The book will also include comprehensive evaluations of the pharmacological treatments available, including novel investigational agents currently in development.

ZDB-2-SME